76 results about "Epidermal Growth Factor Receptor Inhibitors" patented technology

The purpose of this invention is to provide an agent useful for prevention and/or treatment of psychosis, schizophrenia and cognitive impairments. To solve this problem, this invention provides epidermal growth factor receptor inhibitors as therapeutic agents for psychosis, schizophrenia and cognitive impairments.

The invention discloses an EGFR inhibitor. The EGFR inhibitor is of the structure shown in the formula (I) and is a compound including alpha, beta-unsaturated carboxylic acid amides. Meanwhile, the invention discloses a preparing method of the compound and the application of the compound serving as a protein tyrosine kinase inhibitor, especially the inhibiting function on T790M variant EGFR as the EGFR inhibitor, and the application on treating diseases such as the kidney cancer, the ling cancer, the prostate cancer, the pancreatic cancer the breast cancer and the spongiocytoma which are related to EGFR over expression. The structure is shown in the specification.

The invention discloses 3-methoxymethyl-2,3-dihydro-[1,4]dioxano[2,3-f]quinazoline-10-amine compound and a preparation method thereof, and application of the compound as an epidermal growth factor receptor inhibitor for treating cancers, belonging to the field of biology. The compound is an N-substituted phenyl-5-substituted alkoxy-3-methoxymethyl-2,3-dihydro-[1,4]dioxano[2,3-f]quinazoline-10-amine compound as shown in a formula (I) which is described in the specification, or a pharmaceutically acceptable salt or a prodrug molecule thereof. In the formula (I), R<1> is selected from a group consisting of -H, C1-5 straight-chain or branched-chain alkyl groups, alkyloxy groups, alkyloxy-substituted C1-5 straight-chain or branched-chain alkyl groups, etc.; R<2> is selected from a group consisting of -H, halogen, aromatic alkyloxy groups, C1-3 alkyl groups, and C1-3 straight-chain or branched-chain alkoxy groups; and R<3> is selected from a group consisting of -H, halogen, C1-4 unsaturated alkyl groups, nitro groups, cyano groups and C1-3 straight-chain or branched-chain alkoxy groups. The compound provided by the invention can be applied to treatment or prevention a variety of cancers.

The invention relates to phosphate of a compound as shown in the formula (I) which is described in the specification, and a crystal form and a preparation method thereof. The phosphate of the compound has a stable crystal form; the crystal form has favorable performance like good solubility, low hygroscopicity and process developability; and the preparation method is simple and has low cost, so the method has an important value to optimization and development of the phosphate of the compound as a drug in the future.

Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.

The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.

The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and/or nails, which are associated with administration of one or more epidermal growth factor receptor inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.

The invention provides a novel epidermal growth factor receptor inhibitor and an application thereof. The novel epidermal growth factor receptor inhibitor can be used as a T790M variation induced drug-resistant inhibitor.

The invention belongs to the technical field of medical chemistry, and specifically relates to a novel epidermal growth factor receptor inhibitor, a pharmaceutical composition containing the novel epidermal growth factor receptor inhibitor and use of the novel epidermal growth factor receptor inhibitor or the pharmaceutical composition as a cancer prevention and/or treatment medicament. The compounds exhibit excellent EGFR (Epidermal Growth Factor Receptor) inhibition activity, especially for mutative EGFR, and is expected to become a pharmaceutical with a special treatment effect and smaller side effect on resisting pharmaceutical-resistant tumors caused by EGFR mutation.

The invention specifically relates to an indazole-substituted EGFR inhibitor, a pharmaceutical composition containing the inhibitor, and application of the inhibitor or the pharmaceutical composition as a drug for prevention and/or treatment of cancers, belonging to the field of medical chemistry. The inhibitor presents good EGFR inhibitory activity, especially good inhibitory effect on mutant EGFR, and is expected to become a drug with specific curative effect and small side effect on treatment of tumors resistant to drugs due to EGFR mutation.

The invention relates to a kit for forecasting the treatment effect of an epidermal growth factor receptor inhibitor, in particular to a specific primer and a probe for detecting the polymorphism of a nineteenth exon of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the polymorphism of the nineteenth exon of the epidermal growth factor receptor gene through a PCR amplified biological nucleic acid sample, a kit for detecting the polymorphism of the nineteenth exon of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicaments.

The invention relates to the technical field of medicament, in particular to application of an EGFR (Epidermal Growth Factor Receptor) inhibitor in preparation of medicine for treating JE (Japanese Encephalitis). According to the application of the EGFR inhibitor in preparation of the medicine for treating JE, provided by the invention, an important function of the EGFR in JEV (Japanese Encephalitis Virus) infection is discovered, and the EGFR inhibitor has the characteristic of inhibiting the JEV infection; furthermore, the situation that the EGFR inhibitor is capable of influencing the JEV infection through inhibiting phosphorylation of the EGFR is discovered. According to the application of the EGFR inhibitor in preparation of the medicine for treating JE, provided by the invention, the novel medicine is provided for preventing and treating JE, and the market value and a clinic application prospect are better.

The invention provides a traditional Chinese medicinal composition for external use for treating rash. The traditional Chinese medicinal composition is prepared from the following raw medicines: 10 to 50 weight parts of radix scutellariae, 10 to 60 weight parts of herba portulacae, 10 to 60 weight parts of cortex dictamni, 10 to 50 weight parts of radix sophorae flavescentis, and 10 to 60 weight parts of herba taraxaci. The traditional Chinese medicinal composition disclosed by the invention has a remarkable effect on the aspect of improving acne-like rash and itch degree related to EGFRIs (Epidermal Growth Factor Receptor Inhibitors); moreover, an obvious adverse effect is avoided.

The invention relates to a specific primer and a probe for detecting the polymorphism of a twenty-first exon L858R of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the polymorphism of the twenty-first exon L858R of the epidermal growth factor receptor gene through a PCR amplified biological nucleic acid sample, a kit for detecting the polymorphism of the twenty-first exon L858R of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicine.

The invention provides application of a rhinoceros horn and rehmannia glutinosa composition in preparation of a medicine for preventing and treating related rash caused by an epidermal growth factor receptor inhibitor. The rhinoceros horn and rehmannia glutinosa composition includes rhinoceros horns, radix paeoniae rubra, radix rehmanniae and cortex moutan serving as effective ingredients. The medicine composition prepared by rhinoceros horn and rehmannia glutinosa decoction for treating severe hepatitis, hepatic coma, uremia, allergic purpura, acute leukemia, sepsis syndrome and other symptoms is creatively used for preventing and treating the rash caused by the epidermal growth factor receptor inhibitor, is better in clinical curative effect and low in toxicity and can be taken for a long time.

It is an object to provide a culture method which is capable of maintaining and/or culturing iPS cell-derived intestinal stem cells, while maintaining the properties of intestinal stem cells. The induced pluripotent stem cell-derived intestinal stem cell-like cells are cultured in the presence of a GSK-3β inhibitor, a histone deacetylation inhibitor, and a serum replacement, or in the presence of a GSK-3β inhibitor and a serum replacement. Preferably, the culture is carried out under conditions in which one or more compounds selected from the group consisting of an epidermal growth factor, a TGFβ receptor inhibitor and a fibroblast growth factor are further present.

The invention relates to a kit for forecasting the treatment effect of an epidermal growth factor receptor inhibitor, in particular to a specific primer and a probe for detecting the G719S polymorphism locus of an eighteenth exon of an epidermal growth factor receptor gene by a PCR method, application of the same in preparing a reagent for detecting the G719S polymorphism locus of the eighteenth exon of the epidermal growth factor receptor gene through a PCR amplified biological sample, a kit for detecting the G719S polymorphism of the eighteenth exon of the epidermal growth factor receptor gene and application of the kit, and belongs to the field of medicaments.

The invention relates to a natural external pharmaceutical composition. The composition consists of an extract of spinacia oleracea, an extract of flos chrysanthemi indici, a herba violae extract, an extract of honeysuckle flowers and adjuvants. The pharmaceutical composition provided by the invention can be used for preventing or treating rash, and in particular rash caused by an epidermal growth factor receptor inhibitor. The pharmaceutical composition provided by the invention, which is made from natural materials, is simple and easy to prepare and low in cost; and the pharmaceutical composition has the effects of being rapid to take effects, concrete in curative effect and high in safety.

The invention relates to a quinoline or quinazoline derivative with a structure as shown in a formula (I), a pharmaceutical composition containing the compound as shown in the formula (I) and application of the compound in preparation of drugs for preventing or treating human epidermal growth factor receptor Her/erbB family related diseases, and particularly relates to application of the compoundsfor preventing or treating tumors associated with protein tyrosine kinase, wherein each substituent in the formula (I) is the same as the definition in the specification.